


Acrux Limited (ACR:ASX)

ASX Announcement

19 November 2026

Appointment of new Chief Financial Officer and Company Secretary

Melbourne, Australia; 19 November 2026: Acrux Limited (ASX:ACR, "Acrux" or the "Company") announces the appointment of Yelda Adal-Hall as Chief Financial Officer and Lachie Mallia of Bio101 as Company Secretary.

Both appointments will take effect on 25 November 2026, following the Company's Annual General Meeting.

The appointments follow the resignation of Joanna Johnson, who currently holds both positions and will depart the Company at the conclusion of the AGM.

Yelda brings more than 25 years' experience across commercial and not-for-profit organisations to the CFO role, having held senior finance leadership roles at Telspec Australia, Orica (ICI), The Reach Foundation and the Catholic Archdiocese of Melbourne.

Her expertise spans financial strategy, reporting, business planning, treasury, governance and risk management. She has led finance teams through organisational change, strengthened financial controls, and delivered improvements to financial systems and processes. Yelda has extensive experience advising boards and executive teams, on financial performance, strategic planning and risk, supporting effective decision-making and organisational change in diverse and demanding environments. She is a Fellow Certified Practising Accountant (FCPA) and member of CPA Australia.

Acrux has decided to separate the CFO and Company Secretary roles, appointing Lachie Mallia, Director at Bio101 as Company Secretary. The effective date for this appointment will be 25 November 2026.

Lachie is a Chartered Accountant with qualifications in accounting, banking and finance, and governance practice. He has extensive experience in financial and management accounting, company administration and taxation, and acts as CFO and Company Secretary for several life sciences companies.

He is a Director at Bio101, a specialist provider of company secretarial services with extensive experience in the pharmaceutical sector.

For the purposes of ASX Listing Rule 12.6, Lachie will be responsible for communications between the Company and the ASX.

Acrux CEO John Warmbrunn said: *"The appointments of Yelda and Lachie bring valuable financial, governance and life sciences experience to Acrux at an important time for the Company.*

Separating the CFO and Company Secretary roles will allow us to draw on their respective expertise while maintaining our focus on progressing Female Testosterone MDTS towards commercialisation.

I behalf of the Board, I would also like to thank Joanna for her valuable contribution and service to Acrux and wish her all the best for the future."

Authorised for release by the Board of Acrux Limited.

For more information, please contact:

John Warmbrunn
CEO & Managing Director
E: john.warmbrunn@acrux.com.au
P: + 61 3 8379 0100

Investor and Media Relations
Gabriella Hold
The Capital Network
E: gaby@thecapitalnetwork.com.au
P: + 61 2 7257 7338

About Acrux:
Acrux Limited (ASX:ACR) is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States.

Click here to sign up to our InvestorHub and keep up to date with company news and latest developments or for further information on Acrux Limited visit www.acrux.com.au

END.